We identified a novel organic compound,
4-(3'-bromobenzoyl)-6,7-dimethoxyquinazoline (compound WHI-P164), as a potent inhibitor of
triglyceride (TG) synthesis. In an in vitro model of
lipid synthesis,
WHI-P164 (but not any one of the three structurally similar control dimethoxyquinazoline compounds) inhibited the accumulation of TG-rich intracellular lipid droplets in Caco-2 human intestinal cells in a concentration-dependent fashion.
WHI-P164 caused no acute toxicity associated with morbidity or mortality in mice when administered at dose levels ranging from 0.5 to 80 mg/kg. In pharmacokinetic studies in mice,
WHI-P164 was rapidly eliminated from plasma with a terminal elimination half-life of 26.1 +/- 1.3 min after intraperitoneal administration and 33.3 +/- 11.3 min after
intravenous administration. Treatment with 40 mg/kg
WHI-P164 (but not one of three structurally similar control dimethoxyquinazoline compounds) administered intraperitoneally once daily for 7 consecutive treatment days blocked the in vivo hepatic TG synthesis in both
apoE-deficient and wild-type C57B1/6 mice. In
apoE-deficient mice maintained on a high-fat/high-
cholesterol Western diet,
WHI-P164 substantially reduced the
lipid accumulation in the liver after 7 days of treatment and the
lipid accumulation in the aorta after 1 month of treatment. Our results in
apoE-deficient mice show that
lipid accumulation in hepatocytes and foam cells are related events, and inhibiting TG synthesis with
WHI-P164 offers an effective means to treat
atherosclerosis.